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that the newer hypoglycaemic agents will have to stand
comparison with these existing drugs.
At an equal dose schedule the hypoglycaemic effect of
glycodiazine seemed to be more pronounced than that of
tolbutamide. It may compare with tolbutamide in the
rarity of excessive hypoglycaemic reactions since both
substances have a short half-life which tends to prevent
undue accumulation. Glycodiazine may be considered as
an alternative drug to use in patients who have failed to
respond to tolbutamide alone.
It is of interest that a number of patients in the present
study showed improved stabilization with glycodiazine as
compared to that attained on chlorpropamide or phenfor-
min-TD alone. Although normoglycaemia and aglycosuria
was established only in one of these patients, the blood
sugar could be maintained at a lower level in some of the
others. Glycodiazine may thus be worthy of a trial in
patients inadequately stabilized or who exhibit hypogly-
caemic reactions to the long-acting and potentially cumu-
lative sulphonylureas. It is not possible to estimate whether
glycodiazine is more or less powerful than chlorpropamide,
since no comparisons have been made on patients pre-
viously well controlled on chlorpropamide.
The results of this study suggest that glycodiazine, even
in maximum dosage, is likely to be ineffective in materially
influencing the blood-sugar level in patients failing to
respond to a combination of chlorpropamide with a
biguanide. A few patients did, however, achieve somewhat
better control, and 3 of 21 patients showed an initial
response with subsequent failure. On the other hand it
should be emphasized that this group of patients had failed
to respond to combined oral therapy before the trial and
almost all of them appeared to require insulin for adequate
stabilization. If glycodiazine is to be given a trial in these
patients, monthly blood-sugar estimations are mandatory.
GP FOfllll1
Although side-effects were infrequent and minor in the
present study, the number of patients is too small and the
period of treatment too short to evaluate toxicity. Gastro-
intestinal disturbances and skin allergies have been re-
ported in 1·9% and 1·2~o of patients respectively, and a
small number of patients have shown a reduction in leuco-
cyte and platelet count: No toxic effect on the liver has
been recorded to date. Patients who show allergy or light
sensitivity to sulphonylureas are likely to be free of these
complications on glycodiazine because of its different
chemical structure.
SUMMARY
A trial of glycodiazine (as Gondafon), a recently introduced
oral hypoglycaemic agent, is reported in 40 established and
poorly-stabilized diabetic patients.
The results of this study suggest that glycodiazine is an effec-
tive hypoglycaemic agent and that it may reasonably be given
a trial in patients inadequately controlled on tolbutamide,
chlorpropamide or phenformin alone. It is likely to be ineffec-
tive in patients who do not respond to combined therapy with
chlorpropamide and a biguanide, but even here it may pro-
duce some improvement.
Toxic reactions and side-effects are infrequent, and excessive
hypoglycaemia is distinctly uncommon owing to the short
half-life of the drug.
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ACUTE AGRANULOCYTOSIS*
R. SCHAFFER, M.D., Queenstown
In 1922 Werner Schultz' described a clinical entity charac-
terized by sudden onset, severe and rapidly progressive
necrotic lesions in the pharynx, a profound constitutional
disturbance, a marked reduction in the number of circulat-
ing neutrophils, severe toxaemia and death.
Turk' had recognized the condition as early as 1907. The
condition described is acute agranulocytosis.
Not only are the necrotic lesions noted in the pharynx,
but there can also be sloughing in the vagina, in the
gastlo-intestinal tract, the respiratory tract and of the skin.
The leucocyte count may be as low as 250/cu.mm. with
the disappearance of polymorphs, while the red cell count
remains normal.
Kracke3,. in 1931 attributed the increased incidence of
this condition to the increasing use of coal tar derivatives
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as therapeutic agents, and in 1933 Madison and Squier'
reported on amidopyrine as a cause of the condition.
Since drug administration was first blamed for the
occurrence of agranulocytosis and for other blood dyscra-
sias, the numbers of drugs and combination of drugs which
have been incriminated has grown. The Sub-committee on
Blood Dyscrasias of the American Medical Association has
listed more than 450 such drugs.'"
Cyclic neutropenia was described by Reiman and De
Baradiniss in 1949, and primary splenic neutropenia and
chronic hypoplastic neutropenia have also been described,'
but would not appear to be related to the acute agranulo-
cytosis dealt with in this report.
A case of fatal pneumonia, attributed to Achromobacter
anitratus-an organism not usually considered pathogenic
-and associated with profound neutropenia, has recently
been reported by Stockwell et al." I have found blood
culture of little or doubtful value when dealing with acute
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agranulocytosis. Organisms are frequently found which
are there as a result of the agranulocytosis, and such
organisms are unlikely to be a cause of the condition.
I am satisfied that all but one of the cases I have seen
were caused by drug hypersensilivily. The reaction deve-
lops after 7 - IO days' administration of the drug or occurs
on the initiation of a further course of therapy. This type
of sensitization has been most thoroughly documented in
the case of amidopyrine, but can also occur with other
drugs as described by Douglas." I have not seen a typical
case of acute agranulocytosis with profound toxaemia and
death which could not be attributed to a drug containing
amidopyrine.
TABLE I. FATAL CASES OF AGRANULOCYTOSIS SEEN BETWEEN 1924
AND 1965
Onset of Drug causing the
Year Race Age Sex symptoms condition
1926 E 64 M Gradual Neo Sa1varsan (arsenic)
1934 E 15 F Sudden Veramon (amidopyrine)
1934 E 24 M Sudden Veramon (amidopyrine)
1936 E 22 F Sudden Veramon (amidopyrine)
1938 E 45 F Sudden Veramon (amidopyrine)
1963 E 7! F Sudden Orfenso (amidopyrine)
The case seen in 1926 was not typical in that the onset
of the toxaemia was gradual. The patient was a medical
practitioner, and both he and the attending physician had
great faith in the value of arsenicals and an excessive
enthusiasm for this form of therapy, well remembered by
those of us who practised medicine before the antibiotic
era. This was an avoidable death.
I have seen severe neutropenia with necrotic pharyngeal
lesions caused by drugs other than amidopyrine, but these
were neither explosive in onset nor fatal.
rABLE 11. NON-FATAL CASES OF NEUTROPENIA, PYREX lA A D PHARYN-
GEAL ULCERATION
Onselof Drug causing the
Year Race Age Sex symptoms condition
1935 E 29 M Gradual Veramon
1936 E 51 F Gradual Veramon
1939 E J7 F Gradual Sulphanilamide
1939 E 70 F Gradual Veramon
1946 E 49 F Gradual Veramon
I have noted the development of neutropenia while a
patient was under treatment with sulpha drugs, antithyroid
drugs and with phenylbutazone. Such cases are well known
and well documented, and the careful physician prescribes
certain drugs with a full knowledge of the risks involved.
The patient must be kept under strict observation and the
medication stopped on the first evidence of leucopenia
and on the first symptoms which may suggest that all is
not well.
There is a risk involved in the use of many valuable
and occasionally essential drugs. Chloramphenicol may be
essential in the treatment of typhoid and in other condi-
tions and must be used even though it is reported to have
caused aplastic anaemia. Phenylbutazone (Butazolidine)
can be most useful and should not be withheld on
account of the risk of neutropenia, but amidopyrine is
dangerous. A sensitization reaction can develop rapidly,
cannot be controlled, and is usually fatal. It is never
essential to use amidopyrine.
TREATMENT
Massive doses of antibiotics must be used and the newer
penicillins, particularly ampicillin, are probably best.
Steroids should be used in large doses though there is
some doubt whether they are really of value.
Intravenous fluids may be necessary. As there is no
anaemia there is no need for additional blood or additional
haemoglobin, but repeated small transfusions should be
used on the assumption that they may be of value.
The patient must be shielded from any new risk of
infection and, most important of all, other patients and
attendants must be protected from the many virulent
organisms which flourish in the absence of polymorph
nuclear cells.
PROGNOSIS
When the white-cell count is below 1,000 cells/cu.mm. and
the granulocytes below 20%, the prognosis is extremely
grave, but recovery is possible in the younger patient.
In 41 years of practice I have seen 6 fatal cases of
agranulocytosis. Two were men aged 24 and 64 years.
Four were women, the youngest being a schoolgirl of 15
and the oldest 71 years of age. During the same period I
have seen 5 cases which proved not to be fatal. All had
severe neutropenia associated with pyrexia and mucous
membrane ulceration. Four were women and one was a
male of whom the youngest was 17 years of age and the
oldest 70. Five of the fatal cases were seen between 1924
and 1940. One fatal case, to be described in detail, was
seen in 1963. Four of the non-fatal cases were seen be-
tween 1935 and 1940. One was seen in 1946. All of the
patients were White. All except one had taken tablets
containing amidopyrine.
I have seen 6 cases of neutropenia developing while the
patient was under treatment for some other condition. One
case was caused by sulphapyridine; one was attributed to
Thiouracil; 2 cases were attributed to Novalgin (the
offending amidopyrine has now been taken out of this
useful tablet); and 2 cases were taking phenylbutazone
(Butazolidine) for arthritis.
All these patients recovered when the offending medica-
tion was discontinued and did not develop agranulocytosis.
These patients all complained of weakness and of vague
pains. In all, the white-cell count was between 1,500 and
3,OOO/cu.mm. with a relative neutropenia. None of these
patients suffered any permanent ill-effects.
A busy general practitioner, who has had the good for-
tune to be on the staff of a hospital for 40 years and who is
frequently called in as a consultant, has the opportunity of
seeing many interesting· and unusual cases. To have seen 11
cases of agranulocytosis in this period suggests that it is
not a very common condition, but I am satisfied that the
incidence is higher than is suggested by available statistics
and that in many cases a correct diagnosis is not made.
The usual diagnosis 40 years ago was Ludwig's angina. In
some cases the suspected diagnosis was diphtheria. Correct
diagnosis depended then, as it does now, on a high index of
suspicion, and the death certificate does not necessarily
tell the full story. Not only must we have a high index of
suspicion when dealing with the patient, but we also need a
critical mind when we prescribe proprietary preparations.
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The information given by trade representatives and pur-
veyors of samples is no doubt the truth, but is not neces-
sarily the whole truth. Potentially dangerous drugs can
masquerade under innocent-sounding chemical names. The
doctor must know what he prescribes-he is responsible.
There is no doubt that agranulocytosis is not as com-
mon as it used to be. This, in my opinion, is entirely due
to the wide variety of analgesic preparations now avail-
able and to the fortunate reduction in popularity of
amidopyrine-containing preparations_ I have seen only one
fatal case which could not be attributed to amidopyrine.
The most popular, and certainly the most effective,
tablet dispensed both by doctor and chemist used to be
Veramon. It stopped headache, backache and dysmenor-
rhoea. It could be obtained without prescription and was
used both by schoolgirl and grandmother. It was a mixture
of barbitone and amidopyrine and an identical tablet of
South African manufacture was sold at a lower price
under the name of Verosan. The same tablet is still avail-
able under the name of Gano\.
Pyramidon (the trade name of amidopyrine) used to be
almost as popular as aspirin, particularly in Germany, but
is n~) longer in general use in South Africa. Study of the
available literature suggests that amidopyrine alone is not
as dangerous as amidopyrine in combination with other
drugs, and the most dangerous of all is a combination of
amidopyrine and barbiturate. The drug is not always iden-
tified as a constituent of the tablet, because it can masque-
rade under different names. The BPC name is aminopy-
rine; the US National Formulary calls it amidopyrine and
it is also known as aminophenazone, dimethyl aminophena-
zone and dimethyl amino antipyrine. It actually is 4 dime-
thyl amino 2: 3, dimethyl-l-,phenyl pyrazole-5-one.
The first case of agranulocytosis that I diagnosed in my
practice was seen in 1926. The patient was a village general
practitioner aged 64 years. He was being treated by a
friend and colleague for 'Vincent's angina'. He had com-
plained of a sore throat for some weeks and had been
provisionally diagnosed as diphtheria, but the laboratory
found no evidence of diphtheria organisms, but reported
the presence of Vincent organisms. When he failed to
respond to Mandl's paint and phenol gargles, he was
given frequent injections of Neosalvarsan and the throat
was painted at regular intervals with the same arsenical
solution.
After two weeks of this regimen, the temperature re-
mained high, the pulse rapid and thready and the patient
had entered the happy stage referred to in the old text-
books as 'Iow muttering delirium'. When I was asked to
see him in consultation, the right tonsil, uvula and part of
the soft palate had been replaced by a dirty greyish slough.
The white-cell count was 400 cells/cu.mm. He died soon
after I suggested that he be given no more arsenic.
The other 4 fatal cases seen before 1940 could all be
attributed to Veramon. All had complained of general
malaise for about a week. All had been in the habit of
taking Veramon tablets for headache or dysmenorrhoea
and all had taken Veramon during the 2 days preceding
the onset of the acute illness. The onset in all cases was
sudden. All complained of severe sore throat, severe
headache and rapidly progressing weakness. The tempera-
ture varied between 102 °F and 105 °F. The pulse was
rapid. All had necrotic lesions involving tonsillar fossa,
uvula and soft palate. One had a necrotic lesion of the
vulva. All had white-cell counts of I,OOO/cu.mm. or less.
No abnormality of the red-cell series was noted in any of
these patients. All were given intravenous injections of
sodium pentose nucleotide and all were dead within 5 days.
The patients with neutropenia, pyrexia and mucous
membrane ulceration and who recovered had white-cell
counts between 1,500 and 3,OOO/cu.mm. All except one
had taken Veramon and the fifth had taken Sulphanila-
mide. Three we~e given intramuscular sodium pentose
nucleotide (20 m\. daily). Two were given Aolan (filtered
sterilized milk for intramuscular injection) and one of these
was also given intravenous Electrargol, a once-popular
silver preparation used in the treatment of septicaemia.
The therapy used is now of historical interest only, but 1
was satisfied at the time that it was life-saving.
The last case in the series is that of a woman of 71.
She had a painful varicose ulcer. Otherwise her health had
been good. About 5 weeks before her death the ulcer was
very painful and I gave her a sample of a tablet, new at
the time, called Orfenso. Orfenso, which is made in South
Africa, according to a well-advertised Austrian formula,
contains caffeine, paracetamol, amidopyrine, diphonal keto
hexane and some other constituents. It was most effective
and the patient assured me that she had never taken better
tablets.
A week later she developed tonsillitis with a temperature
of 102°F. This responded to Albamycin-T and within 3
days the temperature was normal, but her throat was still
sore. She did not regain her normal strength for about 10
days. Her case record is as follows:
27.8.63-Given sample of Oifenso tablets for painful varicose
ulcer with peripheral vascular spasm. Took 2 tablets daily for
3 days. Pharmacist was given permission to dispense an addi-
tional tube of tablets which were most effective in relieving the
pain. Optulle (paraffin gauze) was used as a dressing for the
ulcer.
3.9.63-1 was called in on account of the temperature,
general malaise and severe sore throat. Right tonsil was en-
larged and there was a purulent exudate on the tonsil. Tonsillar
glands were enlarged and tender. Albamycin-T, 250 mg. 4-
hourly, was prescribed.
6.9.63-Temperature and pulse normal. Still complaining of
sore throat, but general condition good.
1O.9.63-Complaining of backache, pain in the limbs and loss
of appetite. Temperature and pulse normal, urine normal.
Given a vitamin tonic (Elixir B.G. Phos.).
17.9.63-Feeling very much better. Throat fully recovered.
Advised to continue taking the tonic prescribed.
25.9.63-Complained of severe sore throat, backache, head-
ache and pain in the limbs of sudden onset, but did not inform
me that she was ill. Had taken 2 Orfenso tablets per day, on
the 2 preceding days on account of the painful varicose ulcer.
26.9.63-Seen at 6 p.m. Temperature 103°F; pulse 120 per
minute; left tonsil and uvula were replaced by a greyish
slough. There was an ulcer in the mouth. An ulcer was also
noted in the ano-rectal mucosa. She was immediately ad-
mitted to hospital.
Blood count: hnemoglobin 95°~. Total leucocytes 650/cu.
mm., polymorphs 15%, Iymphocytes 85%. Red cells normal.
She was given: (i) Mysteclin V, (tetracycline with a fungi-
cidal pre\?aration, Mycostatin, Nystatin), 250 mg., 4-houriy;
(ii) Predmsone, 10 mg. 4-houriy; (iii) Vitamin B12 , 1,000 mg.;
and (iv) Prostaphlin A, 2 capsules 4-houriy.
27.9.63-0wing to difficulty in swallowing, oral medication
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alternating dextrose saline and dextrose water with the addi-
tion of: 2 million units of penicillin, 40 units of ACIH, 100
mg. of hydrocortisone, and 100 mg. of ascorbic acid, per each
vacolitre. She was given vitamin B12 and Penbritin intramuscu-
larlv.
28.9.63-The patient's condition was deteriorating. There
was now a large slough in the anus, and large slough on the
vulva and a rapidly increasing necrosis in the throat, mouth
and pharynx.
Blood count was: haemoglobin 13·2 G/lOO ml. (89%), leuco-
cytes 350/cu.mm., neutrophils 14% and Iymphocytes 86%. Red
cells normal.
Owing to the deteriorating condition the patient was given
1,000 ml. of fresh blood.
29.9.63-The report on the blood culture sent off on
27.9.63 was positive for Bacillus pyocyaneus. Treatment was
continued with increased dosage of ACIH, hydrocortisone,
penbritin, ascorbic acid, vitamin B" and a repeated blood
transfusion. The nursing staff were given strict instructions to
observe precautions to prevent the spread of the virulent
organisms to other patients or wards.
The patient's condition continued to deteriorate. The sloughs
became larger and there was some rectal haemorrhage after
separation of a slough. Death took place on 4.10.63.
SUMMARY
Werner Schultz in 1922 described a rare disease characterized
by sudden onset, severe and rapidly progressive necrotic lesions
in the pharynx, marked reduction in the number of circulating
neutIOphils, profound toxaemia and death.
In 1931 Kracke attributed the increasing incidence of the
disease to the increasing use of coal tar derivatives as thera-
peutic agents, and soon reports appeared incriminating amido-
pyrine as one of the drugs likely to cause this condition.
More than 450 drugs have been named as possible causes
of blood dyscrasias, but amidopyrine, especially in combina-
tion with barbitone, is the most common cause of acute agra-
Case Report
nulocytosis. It is in all probability a disease caused by drug
hypersensitivity. The reaction develops suddenly after 7 - 10
days' administration of the drug or occurs on the initiation
of a further course of therapy.
Modern treatment with antibiotics, steroids, intravenous
fluid and blood transfusions, has not materially improved the
prognosis. With a total white-cell count of under 1,000/cU.mm.
and polymorphs less than 20% death must be expected.
It is of interest that the erythrocyte count and haemoglobin
level are not disturbed.
In over 40 years of busy practice I have seen 6 fatal cases,
all but one caused by amidopyrine-containing compounds. I
have also seen 5 cases of neutropenia with pyrexia and throat
ulceration which did not develop into typical agranulocytosis.
Four of these cases were attributed to Veramon (amidopyrine
with barbitone) and one was attributed to Sulphanilamide. All
of these patients recovered.
Amidopyrine compounds are again becoming popular. Those
who prescribe them will have many satisfied patients, but may
also, quite unexpectedly, have a death from fatal acute agra-
nulocytosis. There can be no justification for the use of
potentially dangerous drugs, which are never essential.
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ARRHENOBLASTOMA
E. KAHN, * M.B., CH.B. (CAPE TOWN), Associate Director, Department of Obstetrics and Gynaecology,
Livingstone Hospital, Port Elizabeth
The case of a patient with an arrhenoblastoma who pre-
sented as an acute abdominal emergency, is reported here.
Arrhenoblastoma is a rare, predominantly unilateral,
ovarian tumour of mesenchymal origin that causes de-
feminizing and striking masculinizing effects in the female.
It usually occurs in the child-bearing age group and its
malignant potential is estimated at approximately 25%.
This case is presented because of the rarity of this fascinat-
ing tumour and especially because it constituted an acute
abdominal emergency.
BRIEF REVIEW OF THE LITERATURE
Pick is given credit for describing the first case in 1905.
lavert and Finn, however, cite the case of Davis in 1900,
of clinical virilization accompanying an ovarian tumour,
as one of an arrhenoblastoma. In 1931 Meyer suggested
the name 'arrhenoblastoma' when reporting his experience
with 26 cases and also described the three main histologi-
cal types: (1) The well-differentiated tubular adenoma, (2)
the intermediate type, and (3) the undifferentiated sarcoma-
toid variety. He further proposed an origin from male-
directed cells situated in the region of the hilum. In 1940
*Present address: Department of Obstetrics and Gynaecology. Albert Ein-
stein College of Medicine, Bronx, New York.
Kanter and Klawans reported the largest arrhenoblastoma:
it measured 28 cm. in diameter and weighed 4,640 G.
During the past 2 decades several reports, pertaining to
incidence, histogenetic theories, variation of gross and
microscopic appearances and malignant potential, have
appeared. Following Iverson's review in 1947, lavert and
Finn described a 25% malignant potential in their review.
After an all-inclusive discussion Hughesdon and Frasier
suggested an origin from ovarian stroma directly, thus
constituting 'a mixed mesodermal tumour with coelomic,
testicular and Mullerian derivatives'. More recent reviews
have been reported by Pedowitz and O'Brian, Hertig and
Gore, and Fontana and Simpson. From all these reports
it is clear that the tumour varies greatly in its size, shape
and gross appearances, and about 5% are bilateral. Most
authors recommended radical surgical treatment. lavert
and Finn suggest conservative therapy, such as unilateral
oophorectomy-only in the young female who desires
more pregnancies and is stable in weight.
CASE REPORT
The patient was a 36-year-old Negro, gravida 5, para 5, and she
was divorced. Her youngest child was 9 years old. She was
admitted during the night of 22 March 1963 with a history of
sudden onset of acute abdominal pain in the lower abdomen
